BioFinlandin jäsen

Aurealis Therapeutics is a Finnish-Swiss Cell and Gene Therapy Platform Company.

Our multi-target cell and gene therapy platform, based on genetically modified safe lactic acid bacteria, addresses unmet medical needs: Chronic Wounds - Diabetic Foot Ulcers, Venous Ulcers, Pressure Ulcers - deadly Cancers - Ovarian Cancer, Peritoneal Carcinomatosis - and inflammatatory diseases.

After successfully completing Phase 1 and Phase 2 clinical studies for patients with non-healing Diabetic Foot Ulcers (DFU) with our lead clinical product AUP-16 (AUP1602-C), we are preparing for a global Phase 3 pivotal study to be conducted in Europe, USA and China. Studies in Venous Ulcers, Pressure Ulcers, other ulcers, will follow.

In Oncology, we are building on impressive pre-clinical data from multi-targeting bacterial gene therapy AUP-55, which induces tumour regression and improved survival in ovarian and intraperitoneal cancer models.

Our pipeline also includes Inflammation, at discovery stage.